Evidence map›Paper›PMID 34575694›Full record

ArticleJournal of personalized medicine2021

Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline

Florian Reichl, Daniela Muhr, Katharina Rebhan, Gero Kramer, Shahrokh F Shariat, Christian F Singer, Yen Y Tan

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 4 countries.

Florian ReichlDepartment of Obstetrics, Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Daniela MuhrDepartment of Obstetrics, Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Katharina RebhanDepartment of Urology, Medical University of Vienna, Waeringer Guertel 18-20, 1090 Vienna, Austria.
Gero KramerDepartment of Urology, Medical University of Vienna, Waeringer Guertel 18-20, 1090 Vienna, Austria.
Shahrokh F ShariatDepartment of Urology, Medical University of Vienna, Waeringer Guertel 18-20, 1090 Vienna, Austria.
Christian F SingerDepartment of Obstetrics, Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Yen Y TanDepartment of Obstetrics, Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.ORCID 0000-0003-1063-5352
Comprehensive Cancer Center Vienna · ATMedical University of Vienna · ATSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMen with germline

methodsAll men with germline

resultsOf the 323 men included, 45 (13.9%) had a primary cancer diagnosis, many of whom were

conclusionMale BRCA2 carriers were most likely to develop cancer and had worse prognosis. In our dataset, BC was the most common cancer, likely due to referral bias. Not all mutation carriers present with BC or have a family history of cancer to warrant genetic testing.

Indexed as

BRCA mutationscancer spectrumfamily historyhereditary cancermenparent of origin

Identifiers

PMID34575694
PMCPMC8466243
OpenAlexW3200279736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.